ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

02 فبراير 2022 16:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

25 يناير 2022 08:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

10 يناير 2022 08:00:10 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 يناير 2022 16:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

13 ديسمبر 2021 16:15:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

09 ديسمبر 2021 16:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

11 نوفمبر 2021 16:15:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

08 نوفمبر 2021 16:05:01 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

04 نوفمبر 2021 09:00:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

07 أكتوبر 2021 08:55:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

30 سبتمبر 2021 16:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

21 سبتمبر 2021 06:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

01 سبتمبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

16 أغسطس 2021 16:15:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

10 أغسطس 2021 16:05:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

28 يونيو 2021 08:00:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

02 يونيو 2021 16:55:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

26 مايو 2021 16:30:00 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

25 مايو 2021 08:00:03 بحسب Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

06 مايو 2021 16:05:01 بحسب Nasdaq GlobeNewswire